The story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop type 1 diabetes in its tracks.
The film also features board member Karin Hehenberger, shedding light on the patient’s perspective and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in type 1 diabetes.
“If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd Medical team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered. How can I thank you all?" - says Anders Essen-Moller, Chairman of the Board
Diamyd Medical develops the precision medicine Diamyd, currently evaluated in the pivotal phase III clinical trial, DIAGNODE-3.
www.diagnode-3.com